Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. (Q36792968)
Jump to navigation
Jump to search
scientific article published on May 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. |
scientific article published on May 2013 |
Statements
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers (English)
S Aubrey Stoch
Julie A Stone
Deborah L Miller
Lucas van Bortel
Kenneth C Lasseter
Barnali Pramanik
Caroline Cilissen
Qi Liu
Lida Liu
Boyd B Scott
Deborah Panebianco
Yu Ding
Keith Gottesdiener
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference